BRAF-V600 E AND AMELOBLASTOMA: IMMUNOHISTOCHEMICAL STUDY AND CLINICAL-PATHOLOGIC CORRELATION

Some studies have shown that ameloblastoma may show mutation in the BRAF-V600 E gene. Objective: The objective of this study was to evaluate the expression of the mutated BRAF-V600 E protein in cases of unicystic ameloblastoma (UA; n = 22) and multicystic ameloblastoma (MA; n = 18). Study Design: Clinical-pathologic parameters such as age, sex, and tumor location were correlated with positive and negative BRAF expression. Results: All cases of UA were identified in the mandible and only 1 case of MA was located in the maxilla. From the 40 cases, 33 (82.5%) were positive for the anti–BRAF-V600 E antibody, 18 of AU (82%), and 15 of AM (83%). The correlation between the BRAF expression and the variables did not show statistical significance (P> .05). Conclusion: The BRAF-V600 E mutation was frequent in the studied ameloblastomas and it occurs independently of age, sex, and subtype (UA and MA).